InVision Medical Technology
InVision Medical Technology, formerly known as EchoNet and InVision, is a healthcare company specializing in AI tools for interpreting heart ultrasounds and identifying undiagnosed diseases.
Company History
InVision Medical Technology has evolved significantly from its earlier iterations as EchoNet and InVision. With a primary focus on healthcare, InVision Medical Technology operates in the sub-industry of healthcare innovation. The company is backed by YCombinator, having participated in the S22 batch. The team has managed to gain recognition and credibility within the medical community, achieving significant milestones, including peer-reviewed publications in top medical journals and collaborations with leading healthcare entities.
AI Tools for Heart Ultrasounds
InVision Medical Technology develops AI tools designed to streamline the interpretation of heart ultrasounds. These tools aim to identify undiagnosed diseases promptly, serving both patients and healthcare providers. This advanced technology has undergone rigorous testing and has been validated through various peer-reviewed publications in respected medical journals, including Nature, Nature Medicine, Lancet Digital Health, and JAMA Cardiology.
Collaborations and Clinical Trials
InVision Medical Technology has entered into notable collaborations to enhance their AI diagnostics. A significant partnership with Alexion, AstraZeneca Rare Disease focuses on developing an AI algorithm for the early detection of amyloidosis with cardiac involvement. Additionally, the company's results from a blinded and randomized clinical trial evaluating cardiac function were presented as a Late Breaking Clinical Trial at the European Society of Cardiology.
Peer-Reviewed Research Publications
InVision Medical Technology's work has been widely recognized in the scientific community, with research results published in several prestigious medical journals. Their studies have appeared in Nature (2020), Nature Medicine (2021), Lancet Digital Health (2021), and JAMA Cardiology (2022). These publications underscore the company's commitment to advancing medical research and validate the effectiveness of their AI tools.
Y-Combinator and Remote Work Setup
Backed by YCombinator as part of the S22 batch, InVision Medical Technology has a strong foundation for innovation and growth. The company operates with a small but dedicated team of two members in a flexible work environment. Situated as a partly remote organization, InVision Medical Technology leverages the benefits of remote work to enhance productivity and collaboration.
